DUBLIN, Lub Rau Hli 26, 2023– Qhia "Kev Txwv Cov Tshuaj Yeeb Tshuaj Yeeb Nkab - Kev Tshawb Fawb Ntiaj Teb thiab Hauv Cheeb Tsam: Tsom ntsoov rau Peptide Hom, Cov Khoom Siv thiab Kev Tshawb Fawb Hauv cheeb tsam - Kev tshuaj xyuas thiab kev kwv yees, 2024-2040".
Tom qab kev ua lag luam ntxov tshaj plaws ntawm thawj cov tshuaj txwv txwv peptide, kev lag luam thoob ntiaj teb txwv kev lag luam tau kwv yees tias yuav loj hlob los ntawm 2024 txog 2040. Kev lag luam loj yuav tsum ncav cuag $ 60M hauv 2024 thiab $ 17.38B hauv 2040, nrog CAGR ntawm 38.94% dhau. lub sijhawm kwv yees 2025-2040.
Kev lag luam thoob ntiaj teb txwv cov tshuaj peptide yuav tsum muaj kev loj hlob zoo heev thaum lub sijhawm kwv yees los ntawm 2025 txog 2040, uas tau tsav los ntawm ntau qhov kev cog lus ntawm kev ua txhaum tshiab txwv peptide pipeline uas tsis txwv rau cov hom phiaj receptor.Kev nce qib hauv cov cuab yeej siv tshuaj lom neeg, kev nce qib hauv kev lag luam ntawm cov khoom siv hluavtaws peptide kho nyob rau xyoo tas los no, thiab cov nqi pheej yig tau ua tiav los ntawm cov biomolecules hauv ntau cov kab mob yog qee yam ntxiv uas ua rau kev loj hlob ntawm lub sijhawm kwv yees.
Kev tsom xam ntawm qhov cuam tshuam rau lub sijhawm luv thiab ntev yog ua los ntawm cov yam ntxwv uas cuam tshuam rau kev ua lag luam, xws li cov tsav tsheb, kev txwv thiab lub sijhawm.Qhov kev ntsuam xyuas luv luv txiav txim siab lub sijhawm 2020-2025 thiab kev ntsuas mus sij hawm ntev txiav txim siab lub sijhawm 2026-2040.
Cov kev txhim kho tseem ceeb thiab cov tswv yim tau txais los ntawm qee tus neeg tseem ceeb hauv kev ua lag luam no tau suav nrog hauv qhov kev ntsuam xyuas cuam tshuam.Tsis tas li ntawd, cov kev txhim kho tseem ceeb no tau raug soj ntsuam kom nkag siab txog cov hauv kev yav tom ntej rau kev sib koom ua ke cov thev naus laus zis kom ua tiav cov txiaj ntsig zoo.Tsis tas li ntawd, kev pom zoo thiab kev tshaj tawm ntawm cov tuam txhab thiab cov koom haum patent kuj raug coj mus rau hauv tus account thaum soj ntsuam cov kev lag luam thoob ntiaj teb rau cov tshuaj peptide txwv tsis pub peptide.
Kev xav tau thiab kev txwv Cov hauv qab no yog qhov xav tau rau lub ntiaj teb Peptide Dependence Inhibitors kev ua lag luam:
4 Kev Tshawb Fawb Kev Lag Luam 4.1 Kev Taw Qhia 4.1.1 Cov Qauv thiab Kev Tsim Kho ntawm Kev Txwv Peptides 4.1.2 Hom Kev Txwv Peptides 4.2 Evolution of Restricted Peptides 4.3 Kev Loj Hlob Ntawm Kev Txwv Peptides raws li Cov Tshuaj 4.4 Lub Taub Hau Kev Kho Mob 4.5 Cov Tswv Yim Tseem Ceeb Kev Lag Luam - ) ) ) 4.7 Cov kev lag luam tseem ceeb ntawm txoj kev taw qhia 4.8 Cov kev lag luam tseem ceeb - kev vam meej 4.9 Tam sim no kev lag luam loj thiab kev loj hlob muaj peev xwm, USD billion, 2024-2040 thiab txuas ntxiv rau cov tuam txhab tsim cov tshuaj txwv tsis pub siv peptide
5 Properties of conformationally restricted peptides 5.1 Properties of conformationally restricted peptides 5.2 Synthesis of restricted peptides 5.2.1 Chemical ligation of peptides and bridging 5.2.2 Tshuaj ligation ntawm peptides rau scaffolds (CLIPS.5.2.2.2.2.3. Kev tshawb pom (5.2.5 Liquid-Phase Peptide Synthesis (LPPS) 5.2.6 Solid-Phase Peptide Synthesis (SPPS) 5.3 Advances in Peptide Technology 5.3.1 Peptide Synthesis Siv Microfluidics 5.3.2 Solid-Phase Peptide Synthesis.54 Siv Microwaves Xaiv qhov System
6 Cov Ntaub Ntawv Kev Lag Luam 6.1 Txheej txheem cej luam 6.2 Cov teeb meem nrog Kev Tswj Xyuas Kev Pom Zoo rau Txoj Kev Txwv Peptides 6.3 Cov Txheej Txheem Cai rau Kev Txwv Peptides 6.4 US Regulatory Requirements and Structure 6.4.1 Clinical Trial Authorization 6.4.2 Kev Tso Cai Ua Lag Luam 6.4.2 Kev Tso Cai Ua Lag Luam USDA 6.4. txoj cai 6.5 European raws cai thiab lub moj khaum 6.5.1 EMA daim ntawv tso cai txheej txheem 6.5.2 Centralized txheej txheem 6.5.3 Decentralized cov txheej txheem 6.5.4 Mutual recognition cov txheej txheem 6.5.5 National cov txheej txheem 6.6 raws li txoj cai thiab lub moj khaum nyob rau hauv Asia-Pacific cheeb tsam 6.6.1 Cov kev cai lij choj thiab cov qauv hauv Nyij Pooj 6.7 Cov nyiaj them rov qab 6.7.1 Cov kab mob autoimmune reimbursement scenarios 6.7.2 Cancer reimbursement scenarios 6.7.3 Reimbursement scenarios Rare disease
7 Kev Lag Luam Dynamics 7.1 Kev Tshawb Fawb Txog Kev Nyuaj Siab 7.2 Kev Ua Lag Luam Yam Tseem Ceeb 7.2.1 Kev Txhim Kho Kev Ua Lag Luam thiab Kev Txhim Kho ntawm Cellular Uptake 7.2.2 Kev Txhim Kho Ntawm Cov Khoom Siv Hluav Taws Xob 7.2.3 Cov Kev Txwv ntawm Cov Pa Peptides 7.2.4 nce hauv Public thiab Private Funding 7.2.4.1 Cov Nyiaj Txiag Ntawm Cov Tuam Txhab .4.2 Kev Pab Nyiaj los ntawm cov tuam txhab teev npe 7.2.4.3 Kev pab nyiaj los ntawm cov koom haum pej xeem 7.3 Kev lag luam txwv 7.3.1 Kev sib tw ntxiv rau biologics 7.3.2 Kev pheej hmoo ntawm cov tshuaj tiv thaiv kab mob thiab cov khoom tsis zoo ntawm ADME 7.4 Kev ua lag luam 7.4.1 Txwv peptides hauv kev tshawb nrhiav tshuaj 7.4.2 Ntau yam kev siv lub paj hlwb thiab kev kho mob qog noj ntshav
8 Kev sib tw toj roob hauv pes 8.1 Txheej txheem ntawm kev sib tw toj roob hauv pes 8.1.1 Kev txhim kho tseem ceeb 8.1.2 Kev tswj hwm thiab kev cai lij choj kev ua ub no 8.1.3 Kev sib koom ua ke thiab kev yuav khoom 8.1.4 Kev sib koom ua ke 8.1.5 Cov haujlwm nyiaj txiag 8.1.6 Kev txhim kho kho mob
9 Kev lag luam thoob ntiaj teb ntawm kev txwv cov tshuaj peptide (los ntawm cov lus qhia), mln USD, 2024–2040 9.1 Kev Tshawb Fawb Kev Tshawb Fawb Txog Kev Kho Mob Peptide Therapies 9.1.1 Muaj Peev Xwm Phaj II Therapies II) 9.1.2.3 Cov Ntaub Ntawv Ua Haujlwm, Kev Nyab Xeeb, thiab Tolerability Data (Stage 1) 9 . .2.4 Kev Tshawb Fawb Txog Kev Kho Mob ntawm BT5528 9.1.3 PN-9439.1.3.1 Cov Khoom Taw Qhia 9.1.3.2 Kev Tshawb Fawb Tsim (Phase 2) 9.1.3.3 Cov ntaub ntawv ua tau zoo, kev nyab xeeb thiab kam rau ua (Phase II) 9.1.4 PN-23519.1.1. 4.2 Kev tsim qauv (Phase IIb) 9.1.4.3 Cov ntaub ntawv muaj txiaj ntsig, kev nyab xeeb thiab kev tiv thaiv kev tiv thaiv (Phase IIb) 9.1.5 Rusfertide (PTG-300) 9.1.5.1 Cov khoom lag luam saib xyuas 9.1.5.2 Kev Kawm Tsim (Phase II) 9.1.5.3 Kev Ua Haujlwm Zoo, kev nyab xeeb thiab Cov ntaub ntawv tolerability (Phase IIa) 9.1.6 Muaj peev xwm Phase III cov tshuaj 9.1.7 Zilukoplan (RA101495) 9.1.7.1 Cov khoom lag luam nthuav dav 9.1.7.2 Kev kawm tsim (Phase III) 9.1.7.3 Cov ntaub ntawv muaj txiaj ntsig, kev nyab xeeb thiab tolerability (Phase.17.4). Pharmacokinetic thiab pharmacodynamic profile ntawm Zilucoplan (Phase I) 9.1.8 Rusfertide (PTG- 300) 9.1.8.1 Product Overview 9.1.8.2 Study design (Phase III) 9.1.8.3 Efficacy, Safety and tolerability data (Phase II) 9.2 kev loj hlob zoo ntawm lub ntiaj teb no kev ua lag luam rau txwv peptide tshuaj, USD lab, 2024-2040 kev vam meej 9.2.2.2 Tus nqi ntawm API ntau lawm (CDMO)
10 Kev ua lag luam thoob ntiaj teb rau cov tshuaj uas muaj kev txwv peptide (los ntawm hom peptide), US$ mln, 2024-2040 txuas peptide (DRP))
11 Kev ua lag luam thoob ntiaj teb rau cov tshuaj txwv peptide (los ntawm cov khoom muaj peev xwm), mln USD, 2024–2040 (RA101495) 11.1.2.1 API ntau lawm (hauv tsev) 11.1.2.2 API thov kev kwv yees rau 2024-2040 11.1.3 Rusfertide (PT1.130) (PTG-130) .3.1 API Production (Outsourcing) Tus Nqi 11.1.4 PN-94311.1.4.1 API Ntau Lawm (Outsourcing) 11.1.4.2 API Kev Xav Tau Huab Cua 2024-2040
Post lub sij hawm: Jul-06-2023